Figure 2. Infarct area when C21-treatment is delay until 6 hours after stroke.

Histological sections showing typical infarcted (darker area) and non-infarcted regions from SHR that were either treated with (A) vehicle, (B) AT₂R agonist C21 144 µg/kg/dose or (C) C21 144 µg/kg/dose+AT₂R antagonist PD123319 103 µg/kg/dose. Mean data±SEM for infarct volume taken 72 hours post stroke in (D) cortical and (E) striatal regions on the ipsilateral side are shown for vehicle (n = 12), C21 (144 µg/kg/dose; n = 11), PD123319 alone (103 µg/kg/dose; n = 12) and in combination with C21 (144 µg/kg/dose; n = 6). *P<0.05 vs. vehicle (1-way ANOVA).